Welcome to our dedicated page for Clarus Therapeutics Holdings SEC filings (Ticker: BLUWU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women 鈥� including potential therapies for orphan indications. Clarus Therapeutics鈥� first commercial product is JATENZO庐.Magnetar Financial LLC and affiliates filed a Schedule 13G reporting passive ownership of 1,500,000 Class A ordinary shares of Blue Water Acquisition Corp. III (ticker BLUWU) as of 30 Jun 2025. The stake equals 5.77 % of the 25.983 million shares outstanding, meeting the 5 % threshold that triggers Section 13 reporting. The shares are spread across eight Magnetar-managed funds, led by Constellation Master Fund (330 k) and Lake Credit Fund (270 k). Magnetar Financial, Magnetar Capital Partners LP, Supernova Management LLC and manager David J. Snyderman hold shared voting and dispositive power over the entire position; none possesses sole authority. Filed under Rule 13d-1(b) as an investment adviser/holding company, the disclosure states the position is held in the ordinary course of business and not for control purposes. A joint filing agreement and powers of attorney are included.
FAQ
What is the current stock price of Clarus Therapeutics Holdings (BLUWU)?
